AL
RMD icon

Aspiriant LLC’s ResMed RMD Stock Holding History

Aspiriant LLC’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,204
Closed -$275K – 299
2024
Q4 		$275K Sell
1,204
-1
-0.1% -$241 0.01% 243
2024
Q3 		$294K Sell
1,205
-70
-5% -$15.6K 0.01% 234
2024
Q2 		$244K Sell
1,275
-62
-5% -$12.6K 0.01% 256
2024
Q1 		$265K Buy
1,337
+6
+0.5% +$1.1K 0.01% 271
2023
Q4 		$229K Sell
1,331
-90
-6% -$13.8K 0.01% 274
2023
Q3 		$210K Buy
1,421
+65
+5% +$11.8K 0.01% 269
2023
Q2 		$296K Hold
1,356
– – 0.02% 225
2023
Q1 		$297K Hold
1,356
– – 0.02% 220
2022
Q4 		$282K Sell
1,356
-909
-40% -$200K 0.01% 220
2022
Q3 		$494K Buy
2,265
+1,200
+113% +$273K 0.02% 167
2022
Q2 		$224K Buy
+1,065
New +$227K 0.01% 250

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Aspiriant LLC's RMD Position: Q1 2025 in Review

Aspiriant LLC sold out of ResMed (RMD) in Q1 2025, closing a stake of 1,204 shares — an estimated $275K sold.

Aspiriant LLC first reported a position in RMD in Q2 2022 and held it in 11 quarters. The position peaked at $494K in Q3 2022. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

  • Aspiriant LLC reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
  • Aspiriant LLC sold 1,204 ResMed shares in Q1 2025, an estimated $275K.
  • Aspiriant LLC first reported a position in ResMed in Q2 2022 and held it in 11 quarters.
  • Aspiriant LLC's ResMed position peaked at $494K in Q3 2022.
  • 885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on Aspiriant LLC's 13F filing for Q1 2025, filed 21 Apr 2025.